Pramipexole - A new dopamine agonist for the treatment of Parkinson's disease

Journal of the Neurological Sciences

Volumn 163, Issue 1, 1999, Pages 25-31

  Bennett Jr , James P ^a   Piercey, Montford F ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Pharmacia and Upjohn   (United States)

Author keywords

Depression; Dopamine agonist; Neuroprotection; Parkinson's disease; Pramipexole

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE;

ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DEPRESSION; DISTRIBUTION VOLUME; DOPAMINERGIC NERVE CELL; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MOTOR ACTIVITY; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; THIAZOLES;

EID: 0033081353     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00307-4     Document Type: Article

References (34)

1. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., DiPaolo T., Walters R.R., Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP monkeys. J Pharmacol Exp Ther. 272:1995;854-859.
2. 2 receptor mRNA. Brain Res. 564:1991;203-219.
3. Carvey P.M., Pieri S., Ling Z.D. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm. 104:1997;209-228.
4. Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J Neurochem. 71:1998;295-301.
5. Civelli O., Buznow J.R., Grandy K.D. Molecular diversity of the dopamine receptors. Ann Rev Pharmacol Toxicol. 32:1993;281-307.
6. Corrigon M, Piercey M, Sullivan H, Gomez-Mancilla B, Denahan A. The role of dopamine in depression. Am. J. Geriatr Psychiatry, in press.
7. Cummings J.L. Depression and Parkinson's disease: A review. Am J Psychiatry. 149:1992;443-454.
8. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15:1992;133-139.
9. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S. Vo, VonVoigtlander P.F. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742:1996;80-88.
10. 3 receptor subtypes mediate excitatory and inhibitory responses respectively in rat SNPR. Soc. Neurosci Abs. 22:1996;219.
11. Hoffmann W.E., Smith M.W., Piercey M.F. Electrophysiological evidence associating limbic preference with pramipexole, a D3-preferring dopamine agonist. Soc Neurosci Abs. 21:1995;1142.
12. Hu X.-T., Wang R.Y. Comparison of the effects of D1 and D2 dopamine receptor agonists on neurons in the rat caudate putamen: An electrophysiological study. J Neurosci. 8:1988;4340-4348.
13. Kitamura Y., Kohno Y., Nakaazawa M., Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol. 74:1997;51-57.
14. Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology. 49:1997;162-168.
15. Maj J., Rogoz A., Skuza G., Kofodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm. 104:1997;525-533.
16. 2-receptor agonist. Eur J Pharmacol. 215:1992;161-170.
17. 4 receptors. Eur J Pharmacol. 290:1995;29-36.
18. Moore H., Todd C.L., Grace A.A. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra dopamine neurons. J Neurosci. 18:1998;5068-5077.
19. Murer M.G., Dziewczapolski G., Menalled L.B., Garcia M.C., Agid Y., Gershanik O., Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol. 43:1998;561-575.
20. Olanow C.W. Attempts to obtain neuroprotection in Parkinson's disease. Neurology. 49:1997;S26-S33.
21. Parkinson Study Group. Effects of tocopherol and deprenyl in progression of disability in early Parkinson's disease. New Engl J Med 1993;328:176-183.
22. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
23. Parkinson Study Group. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997;49:1168-1170.
24. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. J Am Med Assoc 1997;278:125-30.
25. 3-preferring dopamine agonist: Comparison to other dopamine agonists. Eur J Pharmacol. 312:1996;35-44.
26. 3 receptors. Brain Res. 762:1997;19-28.
27. Shannon K.M., Bennett J.P. Jr., Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 49:1997;724-728.
28. Skirboll L.R., Grace A.A., Bunney B.S. Dopamine auto- and postsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists. Science. 206:1979;80-82.
29. Surmeir D.J., Song W.J., Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci. 16:1996;6579-6591.
30. Szegedi A., Wetzel J., Hillert A., Kleiser E., Gaebel W., Benkert O. Pramipexole, a novel selective dopamine agonist in major depression. Mov Disord. 11(Supp1 1):1996;266.
31. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 115:1994;454-462.
32. Wright C.E., Sisson T.L., Ichhpurani A.K., Peters G.R. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 37:1997;520-525.
33. VonVoigtlander P.F., Fici G.J., Althaus J.S. Pharmacological approaches to counter the toxicity of dopa. Amino Acids. 14:1998;189-196.
34. Yurek D.M., Hipkens S.B., Herbert M.A., Gash D.M., Gerhardt G.A. Age-related decline in striatal dopamine release and motoric function in brown Norway/Fischer 344 hybrid rats. Brain Res. 791:1998;246-256.